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Abstract: Cerebral autosomal-dominant arteriopathy with subcortical infarcts and 
  leukoencephalopathy (CADASIL) is the most common monogenic form of hereditary cere-
bral microangiopathy, and is caused by over 170 different mutations in the NOTCH3 gene at 
locus 19p13.1–13.26. We report the first study of familial CADASIL in a 39-year-old   Jewish 
woman and her mother who had died previously. The patient’s investigations revealed a nor-
mal hemogram with no vascular risk factors or chronic disease. Lumbar puncture was normal. 
Cranial computed tomography scan revealed bilateral diffuse hypodensities in the subcortical 
white matter. Cranial magnetic resonance imaging showed hyperintense lesions in the cere-
bral white matter on T2-weighted images. On electron microscopy, a characteristic granular 
osmiophilic material was seen in the basement membrane surrounding the pericytes and smooth 
muscle cells in small-sized and medium-sized vessels. Molecular analysis of the NOTCH3 
gene was performed with automatic sequencing of exon 3 and 4 (and intron-exon boundaries) 
  showing a nucleotide c.268C . T substitution, leading to a pathogenic amino acid substitu-
tion of p.Arg90Cys, confirming a diagnosis of CADASIL. This mutation was also found in 
the patient’s mother. Although the exact prevalence of CADASIL is not known, this disorder 
has been reported worldwide, and now including Jews, with a genotype and clinical phenotype 
similar to that in other ethnic groups.
Keywords: CADASIL, autosomal-dominant inheritance, genetic diagnostics, NOTCH3, 
arteriopathy
Introduction
The NOTCH signaling pathway system is present in most multicellular organisms 
for cell–cell communication, and involves gene regulation mechanisms that control 
multiple cell differentiation processes during embryonic and adult life. Indeed, it is an 
evolutionarily conserved, intercellular signaling system that plays a crucial role dur-
ing intrauterine vascular and physiological development, contributing to cell destiny 
in many different tissues. NOTCH signals control how cells respond to intrinsic or 
extrinsic developmental stimuli and are necessary to trigger specific developmental 
programs. In addition, NOTCH activity affects the implementation of differentia-
tion, proliferation, and apoptotic programs, serving as a general developmental tool 
which influences organ formation and morphogenesis in all metazoan organisms in 
the animal kingdom.1,2 The name NOTCH (a V-shaped cut) derives from a concavity 
occurring in the wing of Drosophila melanogaster (fruit fly), which carries only one 
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Genes of the NOTCH family encode large single-pass 
transmembrane proteins. The NOTCH receptor is a hetero-
oligomer composed of a large extracellular portion and a 
small intracellular region.4
In mammals, four NOTCH receptors (NOTCH1–
NOTCH4) and five structurally similar NOTCH ligands 
(Delta-like1 [also called Delta-1], Delta-3, Delta-4, Jagged1, 
and Jagged2) have been identified.5–8
The extracellular domain of NOTCH family proteins 
contains a large number of tandem repeat copies of an epider-
mal growth factor-like motif.9 Mutations in genes encoding 
NOTCH pathway components underlie three inherited human 
diseases, ie, Alagille syndrome, spondylocostal dysostosis, 
and cerebral autosomal dominant arteriopathy with subcorti-
cal infarcts and leukoencephalopathy (CADASIL).10–16
The latter is the most common monogenic form of heredi-
tary cerebral angiopathy, and is caused by over 170 different 
mutations in the NOTCH3 gene at chromosome 19,17–19 which 
shows considerable genetic heterogeneity.20,21
In 1996, Joute et al identified a human gene mutation in 
NOTCH3 (NOTCH homolog 3, Drosophila) as the malfunc-
tioning gene causing CADASIL pathology.22 The human 
NOTCH3 gene was mapped to chromosome 19q13.1–13.26, 
where the gene causing CADASIL was also located.23 The 
NOTCH3 gene consists of 33 exons spanning roughly 
7 kb and encodes a transmembrane protein comprising 
2321 amino acids.24
CADASIL is an adult-onset inherited cerebrovascular 
disease characterized by recurrent strokes and progressive 
dementia, with or without migraine-like headaches, seizures, 
pseudobulbar palsy, and depression.25–27 Absence of hyper-
tension or other known vascular risk factors is essential for 
the clinical diagnosis.14,28,29
CADASIL shows true dominancy, and the vast major-
ity of CADASIL mutations (95%) are missense mutations 
removing or inserting cysteine residues within 1–34 epider-
mal growth factor-like repeats in the NOTCH3 protein. Small 
inframe deletions are observed and splice-site mutations in 
the NOTCH3 gene encoding a transmembrane receptor are 
also seen, which invariably cause inframe deletions resulting 
in loss of cysteine residues.30–34
Indeed, six pathogenic deletions, one combined deletion 
and insertion (or two adjacent nucleotide substitutions), 
two duplications, and two splice-site mutations have been 
described. In addition to these common types of cysteine-
affecting CADASIL mutations, seven mutations not altering 
the number of cysteines have been reported. One of these 
mutations is a deletion which removes the amino acids 
between two cysteines, and the remainder are missense 
mutations leading to one amino acid substitution.18,19,22,30,32 
Whether these substitutions are truly pathogenic mutations 
or merely polymorphisms is as yet unclear. So far, only three 
reports of patients homozygous for pathogenic NOTCH3 
mutations have been published.35–37 In addition, two con-
firmed de novo mutations in CADASIL patients have been 
reported.38,39 Thus, either a cysteine residue is deleted or 
altered to another amino acid residue or, conversely, muta-
tions of noncysteine residues lead to introduction of novel 
cysteine residues.32 This results in an uneven number of 
cysteine residues in the given domain, most likely modifying 
the tertiary structure of the protein.31
At least three mechanisms mediate the pathogenic effects 
of NOTCH3 mutation in CADASIL, ie, loss of receptor func-
tion, gain of function, and neomorphic (eg, toxic) processes. 
Mutations of NOTCH3 characteristically lead to an epidermal 
growth factor-like repeat domain (six repeats in the normal 
domain) and an odd number of cysteine residues (either five 
or seven) through gain or loss of a residue.22 No mutations 
leading to three cysteine residues or not involving a cysteine 
residue have ever been reported.31,40 However, it is not yet 
known whether these mutations primarily affect receptor 
trafficking, maturation, and/or signaling.41
Historically, on the basis of thorough scrutiny of the 
literature, the first CADASIL family is now believed to have 
been reported in 1955 by Van Bogaert,42,43 who described two 
sisters with rapidly progressive subcortical encephalopathy 
of Binswanger’s type.44 In 1977, Sourander and Walinder 
reported a Swedish family with a CADASIL mutation and 
multi-infarct dementia of autosomal-dominant inheritance, 
presenting with pyramidal, bulbar, and cerebellar symptoms, 
a relapsing course, and gradually evolving severe dementia.28 
In 2007, Low et al verified that the hereditary multi-infarct 
dementia in the Swedish family reported by Sourander and 
Walinder was erroneously attributed to CADASIL, and 
that the patients did not show the characteristic features of 
CADASIL on pathological examination.45 In Finland, the 
first family with CADASIL was identified and published as 
hereditary multi-infarct dementia in 1987.46 After the gene 
test became available, 15 new families comprising approxi-
mately 100 patients or presymptomatic carriers of the gene 
defect have been identified in Finland. Fourteen of the 15 
families identified in Finland carry the same C475T transition 
mutation of the NOTCH3 gene, which leads to substitution of 
the 133 arginine by cysteine (R133C).19,27,46 Information 
concerning the exact global incidence and prevalence of 
CADASIL is limited. In the west of Scotland, the prevalence Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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of confirmed CADASIL cases in 2004 was 1.98/100,000 and 
the estimated prevalence based on pedigree information was 
4.15/100,000.46 In Finland, a similar prevalence has been 
estimated.48,49
In 1993, Tournier-Lasserve et al applied linkage 
analysis to two large unrelated French families present-
ing with CADASIL (using the acronym CADASIL for 
the first time), and localized the disease to chromosome 
19q12.14 A more recent study by Tikka et al17 investigated 
different pathogenic mutations in 34 patients in France, 
and demonstrated three novel point mutations (p.Cys67Ser, 
p.Cys251Tyr, and p.Tyr1069Cys) and a novel duplication 
(p.Glu434-Leu436dup). In this cohort, the congruence 
between NOTCH3 mutations and deposition of granular 
osmiophilic material around vascular smooth muscle cells, 
which is the gold standard for confirmation of a diagnosis 
of CADASIL, was 100%.17
In 2002, Markus et al performed a large genetic study 
of 48 British families and showed that most mutations of 
CADASIL were located in exon 4, followed by exons 3, 5, 6, 
8, 18, and 22.50 Another study from a Dutch DNA diagnostic 
laboratory (44 Dutch and 22 foreign families) also found 
the mutation rate of CADASIL was highest in exon 4, fol-
lowed by exon 3, 5, 6, 11, and 19.51 Thus, it is suggested that 
exons 3–6 should be screened first, and then exons 11 and 
18–23. In fact, geographic variations have been described, 
showing exon 3 to be the second most common mutation 
site in French, British, and German individuals,32,50–52 while 
exon 11 frequently harbors mutations in affected Dutch 
individuals.51
Epidemiologically, the precise frequency and mortality 
rate of CADASIL worldwide is still unknown. The mean age 
at death has been reported to be 61 years after a mean disease 
duration of approximately 23 years.53 Men tend to die earlier 
than women,19 but mortality appears to be equally distributed 
between the genders, and the onset of clinical symptoms 
usually occurs in the fourth decade of life, with a mean age 
at presentation of 46.1 years.18,53 Fewer than half of patients 
older than 60 years can walk without assistance.54 Nearly 80% 
of patients are completely dependent immediately before 
death.19 However, the number of reported cases of CADASIL 
is gradually increasing as the clinical picture becomes more 
widely recognized and genetic testing becomes available.
CADASIL occurs worldwide and has been reported 
in many ethnic groups. So far, most of the CADASIL 
patients have been found in Caucasian families, including 
France, Germany, the UK, Finland, Sweden, Italy, and the 
Netherlands.15,19,49,50,53,55–59 Reports from North America 
are relatively sparse, despite the high level of academic 
activity in this region, while the numbers of reported cases 
and spectrum of mutations are relatively low in Asia,60,61 
but may reflect an underestimation of the prevalence of 
CADASIL in Asian populations.
In 2007, Bohlega et al62 studied three families from Arab 
countries (Saudi Arabia, Kuwait, and Yemen) containing 19 
individuals affected by CADASIL. All NOTCH3 exons were 
screened for mutations, which revealed the presence of previ-
ously reported mutations in c.406C . T (p.Arg110 . Cys) 
in two families from Saudi Arabia and Kuwait, and a 
c.475C . T (p.Arg133 . Cys) mutation in the family from 
Yemen. The investigators concluded that CADASIL does 
occur in Arabs, with a clinical phenotype and genotype 
similar to that in other ethnic groups.
Clinically, CADASIL, albeit heterogeneous, is associated 
with recurrent stroke (cerebral infarcts) in 70%–80% of cases, 
almost exclusively lacunar infarcts involving the subcorti-
cal white matter, deep gray matter nuclei, and brain stem, 
as well as progressive cognitive impairment (subcortical 
dementia with pseudobulbar palsy and urinary incontinence) 
in 30%–50% of cases are the main clinical manifestations of 
CADASIL. Additional neurological manifestations include 
migraine with aura and stroke.63 In most clinical studies of 
CADASIL, patients are documented to suffer from migraine 
or recurrent headaches; different studies report occurrence 
of migraine in 22%–64% of patients.15 Migraine is usually 
the first symptom, with the mean age of onset in the late 
twenties.25,64–68 CADASIL migraine is typically associated 
with aura. Most often the aura is characteristic, ie, symptoms 
are visual, sensory, aphasic, or have motor features, and may 
also appear in various combinations.
Generally, the first stroke appears at the age of 35–45 
years.69 Strokes are caused by small infarcts, which result 
from fibrosis and obliteration of the lumen and destruction 
of smooth muscle cells in the walls of the cerebral arteries. 
Recurrent infarcts, mainly in the cerebral white matter and 
deep gray matter, lead to cognitive decline and ultimately 
dementia.15,53 Ischemic manifestations of the optic nerve and 
mood disturbance occur in 30% of cases. However, there is 
considerable discrepancy between individuals regarding the 
severity of the phenotype.15,19,53
The pathological hallmark of CADASIL is profound 
demyelination and axonal damage, as well as arteriopathy 
involving distinctive degeneration of the arterial smooth 
muscle cells in the brain and peripheral organs. Magnetic 
resonance imaging (MRI) has enabled quantification of 
the burden of leukoaraiosis and lacunar infarction in the Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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subcortical structures. Hyperintensities in the deep white 
matter, internal and external capsules, and anterior temporal 
pole are characteristic of CADASIL. Increased MRI signals 
in the anterior temporal pole are suggested to be diagnostic 
for CADASIL with 90% sensitivity and 100% specificity. 
White matter impairment and lacunar infarcts can also be 
seen as hypointensities on T1-weighted MRI and computed 
tomography (CT).48
Familial case report  
of CADASIL in Israel
We report the history of the first Israeli family identified 
to have CADASIL, comprising a 39-year-old woman and 
her mother who had died as a consequence of CADASIL 
three years earlier. The patient presented with complaints 
of migrainous headache with aura (for five years), mild 
cognitive impairment (for four years), and dysarthria (for 
two years). In addition, she suffered from vomiting, dizziness, 
blurred vision, photophobia, and numbness on the left side 
two days before her admission to our department in October 
2010. In 2007, she had weakness of both lower limbs, more 
on the left than on the right side. On admission, her inves-
tigations revealed a normal hemogram and no vascular risk 
factors, eg, hypertension, diabetes, or hypercholesterolemia, 
except for moderate triglyceride levels. Lumbar puncture 
showed no abnormality. Cranial CT scan with and without 
contrast revealed diffuse bilateral hypodensities throughout 
the subcortical white matter. Five months later (Figure 1), 
she became mildly forgetful. Cranial MRI done at this time 
showed multiple hyperintense periventricular white matter 
lesions on T2-weighted images (Figures 2, 3, and 4). Carotid 
Doppler studies as well as visual and brainstem evoked 
potentials were normal.
Considering neurodemyelinating disease as an underlying 
pathology, she was given methylprednisolone. Her condition 
continued to deteriorate progressively. Dysarthria became 
more apparent, and left lower motor neuron dysfunction and 
intermittent diplopia were observed. She had mild spastic 
weakness in all four limbs. Tendon jerks were brisk and 
plantar responses were extensor. There was no sensory deficit 
and there were no cerebellar signs. On cognitive examination, 
the patient cooperated satisfactorily in spite of her spastic 
dysarthria and had a score of 19/30 on minimental state 
examination. Examination of other systems was normal.
The patient’s pedigree chart is shown in Figure 6. Her 
mother had had a history of seven years of subcortical 
dementia of unknown etiology, dysarthria, multiple ischemic 
changes, and white matter hypodensities on brain CT scan 
(Figure 5), prior to her death in 2007.
Our patient’s repeat brain MRI done more recently 
revealed confluent and discrete, fairly symmetric, 
T2 hyperintense foci in the deep and subcortical white 
matter of both cerebral hemispheres. Similar foci were pres-
ent in the brainstem, thalami, basal ganglia, and subcortical 
white matter of the anterior temporal lobes. Considering the 
Figure 1 Cranial computed tomography scan revealed bilateral diffuse hypodensities 
over the subcortical white matter.
Figure 2 Magnetic resonance imaging scan of the brain (sagital section) showing 
hyperintensities involving white matter.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  possibility of CADASIL, a skin biopsy was analyzed by 
electron   microscopy, and a molecular analysis for the gene 
defect was done by sequencing the polymerase chain reac-
tion products of exons 3 and 4 of the NOTCH3 gene. The skin 
biopsy revealed characteristic granular osmiophilic material 
within the basement membrane surrounding the pericytes 
and smooth muscle cells of the small-sized and medium-
sized vessels (Figure 7). In addition, molecular analysis 
of the NOTCH3 gene showed a nucleotide substitution at 
c.268C . T, leading to a pathogenic amino acid substitu-
tion of p.Arg90Cys, confirming a diagnosis of CADASIL. 
These findings were similar to the NOTCH3 gene mutation 
and brain biopsy findings for the patient’s mother, which 
were re-examined recently. To our knowledge, this is the 
first familial case of CADASIL to be reported in the Israeli 
population.
Discussion
CADASIL is the most common form of hereditary subcortical 
vascular dementia. It is caused by a defective NOTCH3 gene, 
and over 170 different mutations are known. The main clinical 
features are migraine with aura (often atypical or   isolated), 
Figure 3 Magnetic resonance imaging scan of the brain (coronal section) showing 
hyperintensities involving white matter.
Figure 4 Magnetic resonance imaging scan of the brain showing hyperintensities 
involving  the  temporal  poles  in  the  patient  with  cerebal  autosomal  dominant 
arteriopathy with subcortical infarcts and leuoencephalopathy.
Figure 5 Mother’s cranial computed tomography scan (2007) showing multiple 
ischemic changes and white matter hyperdensities.
CADASIL
Figure 6 Pedigree of the family with cerebal autosomal dominant arteriopathy with 
subcortical infarcts and leuoencephalopathy (CADASIL).Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
388
Shahien et al
strokes, cognitive decline, dementia, and   psychiatric 
  symptoms. Executive and organizing cognitive functions 
are impaired first, and memory is affected later. Typical MRI 
findings are T2-weighted hyperintensities in the temporopolar 
white matter and the capsula externa. Smooth muscle cells in 
the small arteries throughout the body degenerate and vessel 
walls become fibrotic. In the brain, this results in circulatory 
disturbances and lacunar infarcts, mainly in the cerebral white 
matter and deep gray matter. The exact pathogenesis is still 
open. A dominant-negative toxic effect is suggested, possibly 
related to NOTCH3 misfolding. The diagnosis is made either 
by identifying a pathogenic NOTCH3 mutation or by electron 
microscopic demonstration of granular osmiophilic material 
in a skin biopsy.
In this familial study, we describe the clinical and 
neuropsychological features, as well as MRI and skin 
biopsy findings in two Israeli CADASIL patients carrying 
c.268C . T mutation in the NOTCH3 gene on chromosome 
19. Molecular analysis of the NOTCH3 gene mutation was 
performed by automatic sequencing of exon 3 and 4 (and 
intron-exon boundaries) which shows the nucleotide substitu-
tion c.268C . T, leading to a pathogenic amino acid substitu-
tion, ie, p.Arg90Cys, confirming the diagnosis of CADASIL. 
Findings were similar for the patient’s mother. Reports from 
other countries were compared, and were similar to ours. Two 
Chinese families with previously reported NOTCH3 gene 
mutations, ie, c.397C . T and c.268C . T, were identified,70 
and another family report from Iran showed the pathogenic 
amino acid substitution of p.Arg90Cys, confirming a diag-
nosis of CADASIL.71 In addition, two Swedish families 
from Värmlan were also identified to be carrying the same 
mutation as our case, ie, p.Arg90Cys.72
Given the unknown frequency of CADASIL worldwide, 
which may reflect misdiagnosis, or more probably under-
diagnosis, the purposes of this report are to highlight that 
CADASIL also exists in the Israel population, with a geno-
type and clinical phenotype similar to that of other ethnic 
groups, and to underscore the importance of genetic analysis 
in patients who present with subcortical strokes whenever the 
MRI scan reveals significant white matter changes. We also 
wish to raise clinical suspicion of this clinical entity based 
on the presence of a clear family history in the context of 
typical clinical, genetic, and radiological findings. We also 
suggest that screening for mutations in the NOTCH3 gene 
be considered as a diagnostic test for CADASIL. The test 
would involve two steps, ie, initial screening of exons 3 and 4, 
Figure 7 Pathological changes in the capillary: capillary with granular osmiophilic material deposit located in pericyte infolding and thickened basement membrane showing 
collagen fibrils. In addition, endothelial cells are thin.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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and only if no mutations are present, the remaining 31 exons 
should be analyzed. Taken together, clinical, pathological, 
radiological, and molecular studies should make the diag-
nosis straightforward.
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